Aurantio-obtusin is a novel and potent anthraquinone isolated from Semen Cassiae.

AMG319 (also known as ACP319) is a novel, potent, selective, orally bioavailable small molecule inhibitor of PI3Kδ (phosphoinositide-3 kinase δ) with potential anticancer activity.

CZC24832 is a novel, potent and highly selective inhibitor of PI3Kγ (phosphoinostide 3-kinase γ) with a potential for treatment for inflammatory and autoimmune diseases (e.g. RA).

Gedatolisib (also called PF-05212384, PKI-587) is a novel, highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with potential anticancer activity.

BKM120 HCl (also known as NVP-BKM120, or Buparlisib), the hydrochloride salt of BKM-120, is a selective and potent Pan-class I PI3K inhibitor with anticancer activity.

AS-252424 is a novel, potent, orally bioactive and selective PI3Kγ inhibitor with potential anticancer activity.

AZD8835 is a novel, selective, and orally bioavailable inhibitor of the class I (PI3K) catalytic subunit alpha (PIK3CA) PI3Kα and PI3Kδ with IC50s of 6.2 and 5.7 nM, respectively with potential antineoplastic activity.

PI-103 is a novel and potent multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, and has anticancer activity.

GSK1059615 is a novel, potent and reversible inhibitor of P13K (phosphatidylinositol-3-kinases) with potential anticancer activity.

Miransertib (formerly known as ARQ 092) is an orally bioavailable and selective allosteric inhibitor of AKT with IC50 values of 5.0 nM, 4.5 nM, 16 nM for AKT1, 2,and 3, respectively.